DR REDDYS LABORATORIES LTD Form 6-K
November 22, 2017
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November, 2017
Commission File Number 1-15182
DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F	x	Form 40-F "			
Indicate by 101(b)(1): _		egistrant is submitting the	Form 6-K in paper as	permitted by Regulation	S-T Rule
_		(b)(1) only permits the sort to security holders.	ıbmission in paper of a	Form 6-K if submitted s	olely to
Indicate by 101(b)(7): _		egistrant is submitting the	Form 6-K in paper as	permitted by Regulation	S-T Rule
report or of jurisdiction under the ru other docur holders, and	her document that the in which the registrates of the home countent is not a press re	(b)(7) only permits the some registrant foreign prival ant is incorporated, domintry exchange on which elease, is not required to leterial event, has already between the solution of the solu	te issuer must furnish a ciled or legally organiz the registrant's securition te and has not been dist	and make public under the ted (the registrant's "homes are traded, as long as the tributed to the registrant'	e laws of the ne country"), or the report or s security
-		r by furnishing the inform e Commission pursuant t		_	•
Yes "	No x				
If "Yes" is 82		ow the file number assig	ned to registrant in con	nection with Rule 12g3-2	2(b):

## **EXHIBITS**

Exhibit Number	Description of Exhibits
99.1	Press Release, Dr. Reddy's Laboratories announces the launch of generic Azacitidine for Injection in the Canadian Market" dated November 2, 2017.
99.2	Press Release, "Dr. Reddy's Laboratories announces the launch of Clofarabine Injection in the U.S. Market" dated November 11, 2017.
99.3	Notice to Stock Exchanges re: Intimation regarding USFDA audit of Duvvada Formulations Manufacturing Facility dated November 21, 2017.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DR. REDDY'S LABORATORIES LIMITED

(Registrant)

Date: November 22, 2017 By:/s/ Sandeep Poddar

Name: Sandeep Poddar Title: Company Secretary